PolyPid to Participate in the 37th Annual ROTH Conference

PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in the 37th Annual ROTH Conference in Dana Point, California, scheduled for March 17-18, 2025.

Rhea-AI Summary

PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in the 37th Annual ROTH Conference in Dana Point, California, scheduled for March 17-18, 2025.

The company will conduct a fireside chat, which will be available on-demand starting Monday, March 17, 2025, at 2:00 PM PT. Additionally, the management team will engage in one-on-one investor meetings during the event. Interested investors seeking meetings with PolyPid should coordinate through their ROTH representative.

Argus Session date unavailable

-8.29% session move Open Argus

Details

News Market Reaction – PYPD

The recorded move for PYPD in the trading session of this news was -8.29%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PETACH TIKVA, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will present at the 37^th Annual ROTH Conference taking place in Dana Point, California, from March 17-18, 2025.

PolyPid’s fireside chat will be available on-demand beginning on Monday, March 17, 2025, at 2:00 PM PT via the conference platform using the following link.

The PolyPid management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with PolyPid around the conference should contact their ROTH representative.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts:
PolyPid Ltd. 
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is PolyPid (PYPD) presenting at the ROTH Conference 2025?

PolyPid's fireside chat will be available on-demand starting Monday, March 17, 2025, at 2:00 PM PT.

Where is the 37th Annual ROTH Conference with PYPD being held?

The conference is taking place in Dana Point, California.

How can investors meet with PolyPid management at the ROTH Conference?

Investors interested in meeting with PolyPid should contact their ROTH representative to arrange one-on-one meetings.

What is PolyPid's (PYPD) current business focus?

PolyPid is a late-stage biopharma company focused on improving surgical outcomes.